Barely Significant
← all phrases

showed a trend

48,556 sentences · 48,556 papers · 65,371 search hits before verification

In the literature

showed a trendP > 0.051.0× alpha
Adenine intake decreased the diversity and separated microbiota structure Chao1, Observed_species, and Shannon indexes were significantly lower in the NMM group compared with the NC group ( P < 0.05; P < 0.05; P < 0.05), and the above indexes showed a trend of reduction in the NML group ( P > 0.05; P > 0.05; P > 0.05) ( Fig. 4 A–C), suggesting that 50 mg/(kg·d) adenine intake markedly reduced diversity of gut content microbiota of mice.
showed a trendP =0.051.0× alpha
17 Bryne et al demonstrated that six cycles of cyclophosphamide, vincristine, and methotrexate (CVM) consolidation after induction therapy showed a trend toward inferior OS (median OS: 14.1 months vs 19.2 months, P =0.05). 18 In addition to the four studies previously mentioned, other studies also explored the role of CCT in SCLC; however, those studies randomized both limited and extensive stages and came to different conclusions.
showed a trendp < 0.051.0× alpha
The mean waist circumference of female aged 75–79 years was the largest, and showed a trend of first increasing and then decreasing, while the mean waist circumference of female aged over 85 years was significantly lower than that of other groups( p < 0.05) (see Figure 2 ). 3.2.1.3 Waist-to-hip ratio There was no obvious aging trend for males and females.
showed a trendp > 0.051.0× alpha
In addition, we evaluated changes for genes NefH and Ngf, also involved in axonal function, growth, maintenance and neuron survival ( Ryden et al., 1997 ; Hayakawa et al., 2012 ; Turney et al., 2016 ; Fornaro et al., 2020 ) although changes between vehicle and boldine SCI samples were not significant and only showed a trend ( Supplementary Figures 9G, H ; p > 0.05).
showed a trendp=0.051.0× alpha
This is supported by a sub-analysis in KMT2A -rearranged patients, where TRM was similar in both groups, and OS showed a trend towards improvement (63% vs 53%, p=0.05). 11 Despite the lack of benefit in terms of OS in the total cohort, the results of this trial ultimately led to FDA approval for de novo AML patients aged ≥1 month.